65 citations
,
February 2011 in “Molecular cancer therapeutics” CCT128930 is a promising new drug that effectively targets and inhibits a cancer-related protein, showing potential for cancer treatment.
2 citations
,
April 2019 in “Dermatologic Therapy” A patient with alopecia had hair regrowth with tofacitinib but developed a skin reaction, choosing to continue the treatment despite the side effect.
1 citations
,
January 1981 in “Elsevier eBooks” Melatonin stops melanin production after tyrosinase action, with cyclic GMP mimicking this effect.
10 citations
,
August 2016 in “Dermatology Online Journal” Nilotinib can cause skin issues like red bumps and hair loss.
14 citations
,
November 2024 in “Pharmaceuticals” Spanlastic nano-vesicles improve famotidine's effectiveness and absorption.
1 citations
,
February 2025 in “Pediatric Dermatology” Tofacitinib helps hair regrow in some kids with severe alopecia areata, but more research is needed on long-term effects.
June 2017 in “Journal of the American Academy of Dermatology” Tofacitinib is effective and safe for treating severe alopecia areata and related conditions.
51 citations
,
January 2024 in “Nanoscale” Nano-PROTACs could improve drug targeting and delivery by using nanotechnology.
April 2026 in “Reactions Weekly” January 2026 in “Elsevier eBooks” December 2024 in “Reactions Weekly” December 2023 in “Reactions weekly” April 2015 in “Reactions Weekly” November 2014 in “Reactions Weekly” July 2014 in “Reactions Weekly” June 2014 in “Reactions Weekly” January 2014 in “Reactions Weekly” September 2013 in “Reactions weekly” August 2013 in “Reactions Weekly” May 2013 in “Reactions Weekly” January 2013 in “Reactions Weekly” December 2012 in “Reactions Weekly” December 2012 in “Reactions Weekly” August 2012 in “Reactions Weekly” August 2011 in “SpringerReference” August 2011 in “Reactions Weekly” August 2011 in “Reactions Weekly” May 2011 in “Reactions Weekly” March 2011 in “Reactions Weekly” April 2010 in “Reactions Weekly”